Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)
用户4Ud7YDZAY51U
1个月前
38
10
已完结
1. 系统已在2025-05-26 11:51:46对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.ejca.2025.115398
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0959804925001790
其他信息:
出版社: Elsevier BV
作者: Jianming Xu; Lin Shen; Jie Li; Zhiwei Zhou; Chunmei Bai; Zhiping Li; Yihebali Chi; Enxiao Li; Xianjun Yu; Nong Xu; Yuxian Bai; Xiuwen Wang; Xianglin Yuan; Tianshu Liu; Yongmei Yin; Jia Chen; Hanguang Hu; Xingya Li; Dianrong Xiu; Tao Zhang; Wenhui Lou; Jieer Ying; Shukui Qin; Yanhong Deng; Min Tao; Ying Cheng; Songhua Fan; Xian Luo; Xiaojun Guo; Michael M. Shi; Weiguo Su
